| Trial ID: | L0371 |
| Source ID: | IRCT20091114002709N58
|
| Associated Drug: |
Pomegranate
|
| Title: |
The effect of supplementation with pomegranate peel extract on liver enzymes, hs-CRP and lipid profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind clinial trial.
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic fatty liver disease. <br>Fatty (change of) liver, not elsewhere classified;K76.0
|
| Interventions: |
Intervention 1: Intervention group: consumption of two capsules per day (each of them containing 500mg extract of pomegranate peel ) for 12 weeks. Intervention 2: Control group: consumption of two placebo capsules for 10 weeks.
|
| Outcome Measures: |
Alanine aminotransferase (ALT). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Aspartate aminotransferase (AST). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.High density lipoprotein cholesterol (HDL-C). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Low density lipoprotein cholesterol (LDL-C). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Alkaline phosphatase (ALP). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Total cholesterol (TC). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;Triglyceride (TG). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.;High sensitive reactive protein (hs-CRP). Timepoint: At the beginning and at the end of week 10. Method of measurement: Laboratory kit.
|
| Sponsor/Collaborators: |
Iran University of Medical Sciences
|
| Gender: |
All
|
| Age: |
30 years60 years
|
| Phases: |
Phase 3
|
| Enrollment: |
46
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: By random allocation participants will divide into intervention and placebo groups each of which consist of 23 patien
|
| Start Date: |
11/01/2022
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
7 February 2022
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/58875
|
